TRADING ON THE OTC - SYMBOL : PGUZ
OUR PRODUCTS : MEDICAL BACKGROUND & RESEARCH DATA : MANAGEMENT : INVESTORS/NEWS : LINKS : CONTACT US

 

 

 

 

 

Home Page  |  

 

December 18, 2007
PRESS RELEASE 

HARVARD UNIVERSITY COMPLETES  CLINICAL STUDY OF PEGASUS’ HEARTVUE 6S SYSTEM HEART SCREENING DEVICE.

Palm Beach Gardens, FL., Market Wire, December 18th, 2007.  Pegasus Pharmaceuticals/HeartView LLC (Symbol: PGUZ-OTC) today announced the successful completion of the testing protocol for the clinical study of the Company’s HeartVue 6S System screening device, conducted by Harvard University at Massachusetts General Hospital.

The HeartVue 6S System Study involved the screening of 150 patients scheduled for coronary angiography with likely percutaneous coronary intervention.  It included 50 patients who would undergo  coronary intervention within a six month period.  The objectives of this study were to compare images obtained with the HeartVue 6S System before, during and after percutaneous coronary intervention;  to assess the sensitivity and specificity of the System in detecting myocardial ischemia induced during coronary artery occlusion, and to correlate the amount of myocardium at risk with the parameters obtained with the HeartVue 6S System.  The afforded test data will be analyzed and interpreted in early 2008.

In other developments, the Company participated in the MEDICA & COMPAMED 2007 SHOW in Dusseldorf, Germany (November 19th – 22nd, 2007), where it demonstrated the HeartVue 6S System.  The show is the world’s largest medical fair, attracting over 4,300 exhibitors from 100 countries and 137,000 trade visitors.  The Company’s 6S System was received extremely well, and resulted in product distributor inquiries from India, Spain, Portugal, Australia, Germany and Great Britain.

The HeartVue 6S System provides a rapid (1-2 minutes) and accurate assessment of patients with suspected coronary artery disease.  The device uses only 4 limb leads and a dispersion mapping method analysis of low amplitude ECG signals to detect heart abnormalities and ischemia.  The results are then presented as a color-coded 3-dimensional digital heart map which reflects electrical dispersions.  The System will prove to be an invaluable screening tool for cardiologists, general practitioners, clinics, hospitals, the fitness industry, sports teams and emergency medical facilities.

For more information, please contact Paul Davey, Investor Services, at:  (778) 389-0915 (Canada).  Email:  paul@pegasusbiosciences.com or Daniel P. Kesonen, Chairman & CEO of Pegasus Pharmaceuticals Inc., Palm Beach Gardens, FL. At (561) 626-9901.